Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$90.90M-$90.90MN/M vs Q3 2024 EPS Diluted-$1.15-$1.15N/M vs Q3 2024 Operating Income-$96,336,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$72,033,000N/M ended Sep 30, 2025 · filed Nov 3, 2025 · 34 d after period end